Lemonade, Inc. (NYSE:LMND – Get Free Report) insider Maya Prosor sold 30,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $50.00, for a total value of $1,500,000.00. Following the sale, the insider now directly owns 29,286 shares of the company’s stock, valued at $1,464,300. This represents a 50.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Maya Prosor also recently made the following trade(s):
- On Monday, November 11th, Maya Prosor sold 20,000 shares of Lemonade stock. The stock was sold at an average price of $30.00, for a total transaction of $600,000.00.
Lemonade Stock Performance
LMND opened at $49.16 on Thursday. Lemonade, Inc. has a 52-week low of $14.03 and a 52-week high of $53.85. The firm has a market cap of $3.51 billion, a P/E ratio of -16.17 and a beta of 1.68. The business’s fifty day moving average is $24.89 and its 200-day moving average is $20.22.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in shares of Lemonade by 220.0% in the 3rd quarter. Blue Trust Inc. now owns 2,733 shares of the company’s stock valued at $45,000 after purchasing an additional 1,879 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in Lemonade by 321.3% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,462 shares of the company’s stock valued at $74,000 after acquiring an additional 3,403 shares during the last quarter. Quest Partners LLC raised its stake in Lemonade by 1,647.6% during the third quarter. Quest Partners LLC now owns 9,105 shares of the company’s stock worth $150,000 after acquiring an additional 8,584 shares in the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of Lemonade in the second quarter worth about $180,000. Finally, Bristlecone Advisors LLC acquired a new stake in shares of Lemonade in the 3rd quarter valued at approximately $218,000. 80.30% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have weighed in on LMND. Keefe, Bruyette & Woods cut shares of Lemonade from a “market perform” rating to an “underperform” rating and increased their price target for the company from $18.00 to $21.00 in a report on Thursday, November 7th. BMO Capital Markets lifted their price target on Lemonade from $13.00 to $15.00 and gave the stock an “underperform” rating in a report on Thursday, November 21st. JMP Securities upped their price objective on Lemonade from $40.00 to $60.00 and gave the company a “market outperform” rating in a report on Friday, November 22nd. Piper Sandler lifted their target price on Lemonade from $25.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Finally, Morgan Stanley upgraded shares of Lemonade from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $23.00 to $42.00 in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $30.43.
Read Our Latest Analysis on LMND
About Lemonade
Lemonade, Inc provides various insurance products through various channels in the United States, Europe, and the United Kingdom. Its insurance products include stolen or damaged property, and personal liability that protects its customers if they are responsible for an accident or damage to another person or their property.
Featured Stories
- Five stocks we like better than Lemonade
- The Role Economic Reports Play in a Successful Investment Strategy
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Dividend Payout Ratio Calculator
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- With Risk Tolerance, One Size Does Not Fit All
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Lemonade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lemonade and related companies with MarketBeat.com's FREE daily email newsletter.